Impact of Extent of Coronary Artery Disease in Transcatheter Aortic Valve Replacement: A PRO-TAVI Substudy.

What was studied

This study looked at heart patients having a new heart valve placed through a vessel. All 466 people also had coronary artery disease. They were in a trial that compared plans. One plan treated the artery disease before the valve. The other put this step off. The team scored how widespread the artery disease was. Then they compared outcomes at 1 year.

What they found

The main outcome did not differ between the plans at 1 year. It combined death, heart attack, stroke and major bleeding. With a score above 17, death, heart attack or stroke was more frequent with delay. This was driven mainly by deaths and strokes. Bleeding was less frequent with delay in all score groups.

What it means for patients

The authors say putting off the procedure lowered bleeding risk. They say it appeared safe across all score groups. With more complex artery disease, delay was linked to higher risk. This was for death, heart attack or stroke.

Why it is not certain yet

The abstract calls these findings post hoc. The authors say trials need to confirm them. The group with a score above 17 was a subgroup of the 466 people. The abstract does not say how many people were in that subgroup.

Source

Impact of Extent of Coronary Artery Disease in Transcatheter Aortic Valve Replacement: A PRO-TAVI Substudy.

We restate facts from the source record in our own words. The original wording belongs to its publisher.